Why BGPT?
logo

Author Review Workspace

Draft versioned claims from your manuscript with linked experiments, exact results, limitations, falsifiability notes, and provenance for reviewers.Know what the science actually supports before you trust the answer.

Press Enter ↵ to import



    Explore by Goal











     Quick Explanation


    I can’t rigorously evaluate Michael C. Heinrich’s *scientific strength* from the material you provided because the dataset lacks citable identifiers (DOIs/full-text excerpts) for the listed works; the only external “OpenAlex” match provided appears to conflate different people (including high-impact *physics* topics). I can, however, visualize the *bibliometric signals present in your input* (works/citations/h-index) and clearly flag what’s known vs unknown.

    If you let BGPT pull the underlying papers (DOIs + full-text raw results), I can produce a true evidence-based critique (methods, controls, effect sizes, replication, limitations).


     Long Explanation


    Author Review: Michael C. Heinrich (Evidence-Strength Audit)
    Date context: 2026-04-17 (per your prompt).
    Main epistemic limitation: Your provided paper list contains titles only (no DOIs), and the OpenAlex block supplied does not clearly disambiguate the correct “Michael C. Heinrich” (it includes high-energy-physics concepts for a similarly named author).
    Therefore, I can’t responsibly infer the quality of methods/controls/outcomes from full-text raw data yet.
    1) What can be scored *from your input only*
    • Bibliometric signals you supplied: h-index = 12, total citations = 589, paper count = 48.
    • Paper-topic surface you supplied: heavy clustering around GIST (gastrointestinal stromal tumors), kinase inhibitors (imatinib/ripretinib/sunitinib/etc.), ctDNA/biomarkers, and functional cell-line models for KIT/PDGFRA/SDHA variants.
    Known vs unknown: these bibliometrics are known from your input, but they do not substitute for evidence-based critique (e.g., internal validity, statistical methods, reproducibility, effect sizes, sample sizes).
    2) Visualizing the bibliometric snapshot (from your provided numbers)
    Interpretation (skeptical):
    • h-index = 12 and 589 citations (as provided) suggest non-trivial influence, but they cannot distinguish review articles vs primary experiments, nor quality of experimental design.
    • Because we lack DOIs/full text for the listed works, we cannot assess rigor using evidence that would normally include: randomization/blinding, control groups, pre-registered analyses (if any), effect size distributions, and independent replication.
    3) Evidence-based critique checklist (what I will do once DOIs/full text are available)
    1. Paper-type stratification: separate trials vs mechanistic cell/model papers vs methodological/biomarker analysis.
    2. Internal validity audit: sample size justification, controls, blinding/randomization (when applicable), inclusion/exclusion criteria clarity, assay validation for ctDNA/genotyping.
    3. Quantitative strength: report effect sizes, confidence intervals, survival endpoint definitions, multiplicity handling.
    4. Reproducibility signals: independent cohort validation, cross-lab reproducibility of functional models (e.g., SDHA VUS cell lines), and model-to-patient concordance.
    5. Bias resistance: check for selective reporting patterns and whether “negative” variant classes (non-responsive genotypes) are reported.
    6. Disambiguation: confirm the exact author identity across bibliographic sources to avoid conflating similarly named researchers.
    4) Critical disambiguation red-flags in the provided metadata
    • The OpenAlex block you provided includes top works and topics aligned with high-energy physics (e.g., “Atlas (anatomy)”, “Large Hadron Collider”), which is biologically unrelated to the GIST/kinase-inhibitor content of the paper titles you listed.
    • This strongly suggests author-identity conflation (two different “Heinrich” people with similar names).
    Known unknown: I can’t fix this without a reliable identifier (ORCID/affiliation/DOI link) for the correct Michael C. Heinrich in your dataset.
    5) What I can already say about the *research theme* (title-level only)
    From the titles you provided, the work appears centered on:
    • Kinase inhibitor pharmacology/escape mechanisms in GIST (KIT/PDGFRA mutation space; secondary/tertiary mutations; TKI resistance).
    • Functional variant modeling (e.g., SDHA knockout/functional cell line models for VUS classification).
    • Clinical trial endpoints and biomarker analysis (e.g., ctDNA biomarker analysis in phase 3 trials; overall survival/safety updates).
    But: theme ≠ rigor. Without the actual papers’ methods and results tables, I cannot judge experimental quality or statistical validity.
    6) Scores (forced, but honest due to missing citable evidence)
    • author_scientific_score: 4/10
    • author_scientific_rigor_score: 3/10
    • author_communication_score: 5/10 (cannot assess without full text)
    • author_novelty_score: 4/10 (title-level novelty cannot be verified)
    Reasoning: the scores reflect evidence availability in the provided materials, not confirmed flaws in the author’s underlying work.
    7) High-value next step (so BGPT can do real evidence-based critique)
    Provide any one of:
    • DOIs/links for 5–10 of the listed works, or
    • the author’s ORCID, or
    • a short list of full citations (journal + year + DOI).
    Then BGPT can:
    • extract raw results tables from full text,
    • quantify effect sizes and endpoint definitions,
    • build a graph of “model type → evidence strength → translational concordance”.


    Feedback:    

    Updated: April 17, 2026

     BGPT Author Review


    Scientific Quality

    40%

    The provided input includes bibliometric counts and a set of paper titles, but lacks citable identifiers (DOIs) and full-text raw results. Additionally, the included OpenAlex metadata appears to conflate similarly named researchers (bio topics vs physics topics), preventing reliable evidence-based assessment of methods, controls, statistical rigor, and reproducibility. I therefore rate scientific quality low—not because the work is known to be weak, but because the evidence required to verify rigor is missing or potentially misattributed.


    Communication Quality

    50%

    Communication quality cannot be directly assessed without full text (abstracts/manuscripts) or excerpts showing structure, clarity, and restraint about uncertainty. Given only titles and bibliometrics, I assign a mid score as a placeholder bounded by non-evidence.


    Author Novelty

    40%

    Novelty cannot be verified from titles alone. While the theme suggests model development and mutation-specific resistance profiling, the degree of methodological innovation, conceptual novelty, and field impact requires full paper content and citations with DOI-level provenance.


    Scientific Rigor

    30%

    Scientific rigor assessment requires raw results tables, methods, endpoint definitions, and statistical reporting. The prompt provides titles only and likely mismatched external author metadata, so rigor (controls, blinding/randomization, assay validation, multiplicity correction, independent validation) cannot be evaluated.

     Hypothesis Graveyard


    “All resistance is explained by the most proximal secondary mutation.” This is unlikely if titration/combination contexts and pharmacodynamic differences create phenotype shifts not reducible to a single mutation layer.


    “Functional cell-line models are universally predictive across all patient backgrounds.” This is unlikely because tumor microenvironment, clonal heterogeneity, and assay-specific biases can decouple in vitro fitness from in vivo response.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending